Douglas Lowy and Nirali Shah discuss advancements in cancer treatment at the second annual Chasing Cancer Summit
Nirali Shah, M.D., was among the experts featured at the second annual Chasing Cancer Summit on Monday, September 18, 2017 at the Washington Post headquarters in downtown Washington, D.C. Panel discussions centered on the latest developments in cancer detection and treatment. Photo credit: Kris Tripplaar, The Washington Post.
On Monday, September 18, 2017, the second annual Chasing Cancer Summit was held at the Washington Post headquarters in downtown Washington, D.C. The two-hour live event brought together a group of experts for discussions on the latest developments in cancer detection and treatment. The CCR’s Douglas Lowy, M.D., Chief of the Laboratory of Cellular Oncology, and Nirali Shah, M.D., Associate Research Physician in the Pediatric Oncology Branch, were among the group of featured scientists, doctors, patients, policymakers and healthcare innovaters who spoke during the event.
Dr. Shah participated in the panel “Killing Cancer: America’s first FDA-approved gene therapy” with other medical experts and pediatric cancer patient advocate Emily Whitehead, the first pediatric recipient of experimental gene therapy for cancer. The group examined recent innovations in cancer treatment, including immunotheraphy and CAR T-cell treatment.
Dr. Lowy joined Otis Brawley, M.D., of the American Cancer Society and Jill Hagenkord, M.D., F.C.A.P., of Color Genomics and others for “Coding Cancer: When medicine and technology converge” to discuss the latest developments in cancer detection, prevention and treatment.
An archived version of the Killing Cancer: American’s first FDA-approved gene therapy panel is also available.Summary Posted: Fri, 09/01/2017